Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

Arthritis and Rheumatism

Volumn 54, Issue 9, 2006, Pages 2793-2806

  Cohen, Stanley B ^a   Emery, Paul ^b   Greenwald, Maria W ^c   Dougados, Maxime ^d   Furie, Richard A ^e   Genovese, Mark C ^f   Keystone, Edward C ^g   Loveless, James E ^h   Burmester, Gerd Rüdiger ⁱ   Cravets, Matthew W ^j   Hessey, Eva W ^k   Shaw, Timothy ^k   Totoritis, Mark C ^j  

^a RADIANT RESEARCH   (United States)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

^c Desert Medical Advances   (United States)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e North Shore Long Island Jewish Health System ^*  (United States)

^f STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

^h Intermountain Orthopedics   (United States)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j BIOGEN   (United States)

^k ROCHE PRODUCTS LTD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CD20 ANTIGEN; CYCLOSPORIN; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; PENICILLAMINE; PLACEBO; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RHEUMATOID FACTOR; RITUXIMAB; SALAZOSULFAPYRIDINE; TRIAMCINOLONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; AMERICAN COLLEGE OF RHEUMATOLOGY 20 PERCENT IMPROVEMENT CRITERIA; AMERICAN COLLEGE OF RHEUMATOLOGY 50 PERCENT IMPROVEMENT CRITERIA; AMERICAN COLLEGE OF RHEUMATOLOGY 70 PERCENT IMPROVEMENT CRITERIA; ARTHRALGIA; ARTICLE; B LYMPHOCYTE; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY SCORE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INFUSION; DRUG RESISTANCE; DRUG SAFETY; DRUG TREATMENT FAILURE; EUROPEAN LEAGUE AGAINST RHEUMATISM RESPONSE CRITERIA; FATIGUE; FEMALE; FEVER; FOLLOW UP; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE; GENANT MODIFIED SHARP RADIOGRAPHIC SCORE; HEADACHE; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION; LONG TERM CARE; MALE; MULTICENTER STUDY; NAUSEA; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SCORING SYSTEM; SHORT FORM 36; SINGLE DRUG DOSE; SINUSITIS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PLACEBOS; SAFETY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33746961890     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22025     Document Type: Article

References (41)

1. Sangha O. Epidemiology of rheumatic diseases. Rheumatology (Oxford) 2000;39 Suppl 2:3-12.
2. Smith JB, Haynes MK. Rheumatoid arthritis-a molecular understanding. Ann Intern Med 2002;136:908-22.
3. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-9.
4. Corbett M, Dalton S, Young A, Silman A, Shipley M. Factors predicting death, survival and functional outcome in a prospective study of early rheumatoid disease over fifteen years. Br J Rheumatol 1993;32:717-23.
5. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984;27:864-72.
6. Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:353-63.
7. Lipsky PE, van der Heijde DM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, et al, and the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
8. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
9. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
10. Feltelius N, Fored CM, Blomqvist P, Bertilsson L, Geborek P, Jacobsson LT, et al. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis 2005;64:246-52.
11. Van Vollenhoven RF, Carli CC, Bratt J, Klareskog L. Six year report of the STURE Registry for biologicals in rheumatology: satisfactory overall results but plenty of room for improvement [abstract]. Arthritis Rheum 2005;52 Suppl 9:S135.
12. Edwards JC, Cambridge G, Abrahams VM. Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology 1999;97:188-96.
13. Panayi GS. The immunopathogenesis of rheumatoid arthritis. Br J Rheumatol 1993;32 Suppl 1:4-14.
14. Dorner T, Burmester GR. The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr Opin Rheumatol 2003;15:246-52.
15. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-79.
16. Metlay JP, Pure E, Steinman RM. Control of the immune response at the level of antigen-presenting cells: a comparison of the function of dendritic cells and B lymphocytes. Adv Immunol 1989;47:45-116.
17. Pistoia V, Corcione A. Relationships between B cell cytokine production in secondary lymphoid follicles and apoptosis of germinal center B lymphocytes. Stem Cells 1995;13:487-500.
18. Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001;167:4710-8.
19. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45.
20. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001;40:205-11.
21. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
22. Anderson DR, Grillo-Lopez A, Varns C, Chambers KS, Hanna N. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans 1997;25:705-8.
23. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000;6:443-6.
24. Sell S, Max EE. All about B cells. In: Sell S, Max EE, editors. Immunology, immunopathology, and immunity. 6th ed. Washington DC: ASM Press; 2001. p. 101.
25. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
26. Genant HK, Jiang Y, Peterfy C, Lu Y, Redei J, Countryman PJ. Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum 1998;41:1583-90.
27. Cancer Therapy Evaluation Program: Common Toxicity Criteria version 2.0 (CTC). Bethesda (MD): Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 1998.
28. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
29. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
30. Van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40.
31. Kirwan JR, for the Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995;333:142-6.
32. Gause A, Berek C. Role of B cells in the pathogenesis of rheumatoid arthritis: potential implications for treatment. Bio-Drugs 2001;15:73-9.
33. Reparon-Schuijt CC, van Esch WJ, van Kooten C, Ezendam NP, Levarht EW, Breedveld FC, et al. Presence of a population of CD20+, CD38- B lymphocytes with defective proliferative responsiveness in the synovial compartment of patients with rheumatoid arthritis. Arthritis Rheum 2001;44:2029-37.
34. Shiokawa S, Matsumato N, Nishimura J. Clonal analysis of B cells in the synovial membrane of patients with rheumatoid arthritis. Scand J Rheumatol 2003;32:12-8.
35. Zhang Z, Bridges SL Jr. Pathogenesis of rheumatoid arthritis. Role of B lymphocytes. Rheum Dis Clin North Am 2001;27:335-53.
36. Kimbey E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005;31:465-73.
37. McLaughlin P, Hagemeister FB, Grillo-Lopez AJ. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol 1999;26 Suppl 14:79-87.
38. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Close D, Stevens RM, et al. Efficacy and safety of rituximab, a B-cell targeted chimeric monoclonal antibody: a randomized, placebo-controlled trial in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2002;46 Suppl 9:S197.
39. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al, for the DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase lib randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
40. Emery P, Sheeran T, Lehane PB, Saiedabadi N, Shaw TM. Efficacy and safety of rituximab at 2 years following a single treatment in patients with active rheumatoid arthritis [abstract]. Arthritis Rheum 2004;50 Suppl 9;S659.
41. Pavelka K, Emery P, Filipowicz-Sosnowska A, Nahir M, Kaell A, Baldassare A, et al. Efficacy and safety following repeated courses of rituximab in patients with active rheumatoid arthritis [abstract]. Ann Rheum Dis 2005;64 Suppl III:435.